Literature DB >> 28475401

Cellular identity crisis: Antiandrogen resistance by lineage plasticity.

Daniel Tuerff1, Tristan Sissung1, William D Figg1.   

Abstract

A recent publication in Science demonstrates the ability of prostate cancer cells to switch lineages from one that is dependent on androgen signaling to a cell type that is not. Known as lineage plasticity, this phenomenon is driven by the transcription factor SOX2 in RB1 and TP53-deficient prostate cancer. SOX2 is a potential prognostic marker and therapeutic target in castration resistant prostate cancer.

Entities:  

Keywords:  CRPC; Lineage plasticity; RB1; SOX2; TP53; antiandrogen; prostate cancer

Mesh：

Substances：

Year:  2017        PMID： 28475401      PMCID： PMC5710664          DOI： 10.1080/15384047.2017.1323599

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN： 1538-4047            Impact factor:   4.742


  9 in total

1.  Overexpression of SOX2 is involved in paclitaxel resistance of ovarian cancer via the PI3K/Akt pathway.

Authors:  Yang Li; Kangdong Chen; Lei Li; Rui Li; Juxin Zhang; Wu Ren
Journal:  Tumour Biol       Date:  2015-07-11

2.  SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer.

Authors:  Ping Mu; Zeda Zhang; Matteo Benelli; Wouter R Karthaus; Elizabeth Hoover; Chi-Chao Chen; John Wongvipat; Sheng-Yu Ku; Dong Gao; Zhen Cao; Neel Shah; Elizabeth J Adams; Wassim Abida; Philip A Watson; Davide Prandi; Chun-Hao Huang; Elisa de Stanchina; Scott W Lowe; Leigh Ellis; Himisha Beltran; Mark A Rubin; David W Goodrich; Francesca Demichelis; Charles L Sawyers
Journal:  Science       Date:  2017-01-06       Impact factor: 47.728

3.  Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance.

Authors:  Sheng Yu Ku; Spencer Rosario; Yanqing Wang; Ping Mu; Mukund Seshadri; Zachary W Goodrich; Maxwell M Goodrich; David P Labbé; Eduardo Cortes Gomez; Jianmin Wang; Henry W Long; Bo Xu; Myles Brown; Massimo Loda; Charles L Sawyers; Leigh Ellis; David W Goodrich
Journal:  Science       Date:  2017-01-06       Impact factor: 47.728

4.  Sox2 is required to maintain cancer stem cells in a mouse model of high-grade oligodendroglioma.

Authors:  Rebecca Favaro; Irene Appolloni; Serena Pellegatta; Alexandra Badiola Sanga; Pierfrancesco Pagella; Eleonora Gambini; Federica Pisati; Sergio Ottolenghi; Maria Foti; Gaetano Finocchiaro; Paolo Malatesta; Silvia K Nicolis
Journal:  Cancer Res       Date:  2014-03-05       Impact factor: 12.701

Review 5.  Neuroendocrine Prostate Cancer (NEPC) progressing from conventional prostatic adenocarcinoma: factors associated with time to development of NEPC and survival from NEPC diagnosis-a systematic review and pooled analysis.

Authors:  Hai Tao Wang; Yan Hong Yao; Bao Guo Li; Yong Tang; Ji Wu Chang; Jiao Zhang
Journal:  J Clin Oncol       Date:  2014-09-15       Impact factor: 44.544

6.  miR-34 miRNAs provide a barrier for somatic cell reprogramming.

Authors:  Yong Jin Choi; Chao-Po Lin; Jaclyn J Ho; Xingyue He; Nobuhiro Okada; Pengcheng Bu; Yingchao Zhong; Sang Yong Kim; Margaux J Bennett; Caifu Chen; Arzu Ozturk; Geoffrey G Hicks; Greg J Hannon; Lin He
Journal:  Nat Cell Biol       Date:  2011-10-23       Impact factor: 28.824

Review 7.  SOX2 and cancer: current research and its implications in the clinic.

Authors:  Kasia Weina; Jochen Utikal
Journal:  Clin Transl Med       Date:  2014-07-04

Review 8.  The Present and Future of Biomarkers in Prostate Cancer: Proteomics, Genomics, and Immunology Advancements.

Authors:  Pierre-Olivier Gaudreau; John Stagg; Denis Soulières; Fred Saad
Journal:  Biomark Cancer       Date:  2016-05-05

9.  Targeted silencing of the oncogenic transcription factor SOX2 in breast cancer.

Authors:  Sabine Stolzenburg; Marianne G Rots; Adriana S Beltran; Ashley G Rivenbark; Xinni Yuan; Haili Qian; Brian D Strahl; Pilar Blancafort
Journal:  Nucleic Acids Res       Date:  2012-05-04       Impact factor: 16.971
  9 in total
  2 in total

1.  Androgen Deprivation Induces Transcriptional Reprogramming in Prostate Cancer Cells to Develop Stem Cell-Like Characteristics.

Authors:  Shiv Verma; Eswar Shankar; F Naz Cemre Kalayci; Amrita Mukunda; Malek Alassfar; Vaibhav Singh; E Ricky Chan; Gregory T MacLennan; Sanjay Gupta
Journal:  Int J Mol Sci       Date:  2020-12-16       Impact factor: 5.923

2.  Androgen receptor-mediated transcriptional repression targets cell plasticity in prostate cancer.

Authors:  Éva Erdmann; Pauline Ould Madi Berthélémy; Félicie Cottard; Charlotte Zoe Angel; Edwige Schreyer; Tao Ye; Bastien Morlet; Luc Negroni; Bruno Kieffer; Jocelyn Céraline
Journal:  Mol Oncol       Date:  2022-02-02       Impact factor: 7.449
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.